WallStreetZenWallStreetZen

NASDAQ: CTSO
Cytosorbents Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CTSO

Based on 2 analysts offering 12 month price targets for Cytosorbents Corp

Min Forecast
$1.00-2.91%
Avg Forecast
$5.50+433.98%
Max Forecast
$10.00+870.87%

Should I buy or sell CTSO stock?

Based on 2 analysts offering ratings for Cytosorbents Corp.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTSO stock forecasts and price targets.

CTSO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-03
lockedlocked$00.00+00.00%2025-04-01

1 of 1

Forecast return on equity

Is CTSO forecast to generate an efficient return?

Company
-39.39%
Industry
20.86%
Market
81.76%
CTSO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTSO forecast to generate an efficient return on assets?

Company
-9.24%
Industry
13.29%
CTSO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTSO earnings per share forecast

What is CTSO's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.25
Avg 2 year Forecast
-$0.14
Avg 3 year Forecast
-$0.11

CTSO revenue forecast

What is CTSO's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$38.6M+8.49%
Avg 2 year Forecast
$44.2M+24.13%
Avg 3 year Forecast
$52.2M+46.54%
CTSO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTSO revenue growth forecast

How is CTSO forecast to perform vs Medical Devices companies and vs the US market?

Company
13.08%
Industry
8.04%
Market
10.4%
CTSO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTSO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTSO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CTSO$1.03$5.50+433.98%Buy
ICCM$1.13$2.50+122.22%Buy
XTNT$0.45N/AN/A
HYPR$0.70$1.33+91.09%Strong Buy
SRTS$4.59$13.00+183.22%Strong Buy
View Top Medical Device Stocks

Cytosorbents Stock Forecast FAQ

Is Cytosorbents Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CTSO) stock is to Buy CTSO stock.

Out of 2 analysts, 1 (50%) are recommending CTSO as a Strong Buy, 0 (0%) are recommending CTSO as a Buy, 1 (50%) are recommending CTSO as a Hold, 0 (0%) are recommending CTSO as a Sell, and 0 (0%) are recommending CTSO as a Strong Sell.

If you're new to stock investing, here's how to buy Cytosorbents stock.

What is CTSO's earnings growth forecast for 2025-2027?

(NASDAQ: CTSO) Cytosorbents's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 16.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Cytosorbents's earnings in 2025 is -$20,718,957.On average, 2 Wall Street analysts forecast CTSO's earnings for 2025 to be -$15,312,500, with the lowest CTSO earnings forecast at -$15,625,000, and the highest CTSO earnings forecast at -$15,000,000. On average, 2 Wall Street analysts forecast CTSO's earnings for 2026 to be -$8,437,500, with the lowest CTSO earnings forecast at -$10,625,000, and the highest CTSO earnings forecast at -$6,250,000.

In 2027, CTSO is forecast to generate -$6,875,000 in earnings, with the lowest earnings forecast at -$6,875,000 and the highest earnings forecast at -$6,875,000.

What is CTSO's revenue growth forecast for 2025-2027?

(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 13.08% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Cytosorbents's revenue in 2025 is $35,594,520.On average, 2 Wall Street analysts forecast CTSO's revenue for 2025 to be $2,413,437,500, with the lowest CTSO revenue forecast at $2,339,375,000, and the highest CTSO revenue forecast at $2,487,500,000. On average, 2 Wall Street analysts forecast CTSO's revenue for 2026 to be $2,761,562,500, with the lowest CTSO revenue forecast at $2,631,875,000, and the highest CTSO revenue forecast at $2,891,250,000.

In 2027, CTSO is forecast to generate $3,260,000,000 in revenue, with the lowest revenue forecast at $3,260,000,000 and the highest revenue forecast at $3,260,000,000.

What is CTSO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CTSO) forecast ROA is -9.24%, which is lower than the forecast US Medical Devices industry average of 13.29%.

What is CTSO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CTSO price target, the average CTSO price target is $5.50, with the highest CTSO stock price forecast at $10.00 and the lowest CTSO stock price forecast at $1.00.

On average, Wall Street analysts predict that Cytosorbents's share price could reach $5.50 by Apr 3, 2026. The average Cytosorbents stock price prediction forecasts a potential upside of 433.98% from the current CTSO share price of $1.03.

What is CTSO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CTSO) Cytosorbents's current Earnings Per Share (EPS) is -$0.38. On average, analysts forecast that CTSO's EPS will be -$0.25 for 2025, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at -$0.24. On average, analysts forecast that CTSO's EPS will be -$0.14 for 2026, with the lowest EPS forecast at -$0.17, and the highest EPS forecast at -$0.10. In 2027, CTSO's EPS is forecast to hit -$0.11 (min: -$0.11, max: -$0.11).

What is CTSO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CTSO) forecast ROE is -39.39%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.